NASDAQ:BTAI - BioXcel Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $102.00
Forecasted Upside: 310.30 %
Number of Analysts: 10
Breakdown:
0 Sell Ratings
0 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$24.86 As of 07/23/2021 01:00 AM ET

▼ -1.08 (-4.16%)

1 month | 3 months | 12 months

Get New BioXcel Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BTAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTAI

^$102.00

▲ +310.30% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for BioXcel Therapeutics in the last 3 months. The average price target is $102.00, with a high forecast of $140.00 and a low forecast of $60.00. The average price target represents a 310.30% upside from the last price of $24.86.

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in BioXcel Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/28/2021	HC Wainwright	Lower Price Target	Buy	$176.00 ➝ $140.00	Low
6/23/2021	Truist Securities	Lower Price Target	Buy	$128.00 ➝ $125.00	High
6/1/2021	HC Wainwright	Boost Price Target	Buy	$170.00 ➝ $176.00	High
5/11/2021	HC Wainwright	Lower Price Target	Buy	$175.00 ➝ $170.00	High
4/9/2021	Berenberg Bank	Initiated Coverage	Buy	$75.00	Low
4/1/2021	Truist	Lower Price Target		$150.00 ➝ $127.00	High
4/1/2021	Truist Securities	Lower Price Target	Buy	$150.00 ➝ $127.00	High
4/1/2021	HC Wainwright	Lower Price Target	Buy	$185.00 ➝ $175.00	High
4/1/2021	Canaccord Genuity	Lower Price Target	Buy	$110.00 ➝ $95.00	High
2/1/2021	UBS Group	Initiated Coverage	Buy	$99.00	Low
1/6/2021	HC Wainwright	Boost Price Target	Buy	$175.00 ➝ $185.00	N/A
12/28/2020	Truist Financial	Reiterated Rating	Buy		N/A
11/18/2020	Canaccord Genuity	Boost Price Target	Buy	$108.00 ➝ $110.00	High
10/30/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$60.00	High
9/2/2020	Jefferies Financial Group	Initiated Coverage	Buy	$82.00 ➝ $82.00	High
8/17/2020	Guggenheim	Boost Price Target	Buy	$101.00 ➝ $122.00	High
8/17/2020	BMO Capital Markets	Lower Price Target	Outperform	$104.00 ➝ $95.00	High
8/17/2020	HC Wainwright	Lower Price Target	Buy	$200.00 ➝ $175.00	High
8/14/2020	Canaccord Genuity	Reiterated Rating	Buy	$120.00 ➝ $108.00	High
7/21/2020	Canaccord Genuity	Boost Price Target	Positive ➝ Buy	$71.00 ➝ $120.00	Medium
7/20/2020	BMO Capital Markets	Boost Price Target	Outperform ➝ Positive	$64.00 ➝ $104.00	High
7/20/2020	HC Wainwright	Boost Price Target	Buy	$120.00 ➝ $200.00	High
7/13/2020	Bank of America	Boost Price Target	Buy	$53.00 ➝ $63.00	High
7/6/2020	HC Wainwright	Reiterated Rating	Buy	$120.00	High
6/24/2020	HC Wainwright	Reiterated Rating	Buy	$95.00	Medium
6/11/2020	HC Wainwright	Reiterated Rating	Buy	$95.00	Medium
6/4/2020	Guggenheim	Initiated Coverage	Buy	$101.00	High
5/13/2020	HC Wainwright	Reiterated Rating	Buy	$95.00	High
5/13/2020	Canaccord Genuity	Reiterated Rating	Buy	$71.00	High
5/1/2020	Canaccord Genuity	Reiterated Rating	Buy	$68.00	High
4/28/2020	HC Wainwright	Reiterated Rating	Buy	$95.00	High
4/1/2020	Bank of America	Initiated Coverage	Buy	$45.00	High
3/19/2020	HC Wainwright	Reiterated Rating	Buy	$95.00	High
3/10/2020	BMO Capital Markets	Boost Price Target		$26.00 ➝ $64.00	High
3/10/2020	Canaccord Genuity	Reiterated Rating	Buy		Low
2/5/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	High
1/16/2020	BMO Capital Markets	Reiterated Rating	Outperform ➝ Positive	$26.00	High
1/8/2020	HC Wainwright	Reiterated Rating	Buy	$25.00 ➝ $30.00	High
12/31/2019	Canaccord Genuity	Boost Price Target	Buy	$24.00 ➝ $27.00	Low
12/30/2019	HC Wainwright	Initiated Coverage	Buy	$25.00	High
12/11/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	High
11/20/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	Medium
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$24.00	High
9/18/2019	BMO Capital Markets	Set Price Target	Buy	$21.00	Low
8/21/2019	HC Wainwright	Set Price Target	Buy	$25.00	Low
6/5/2019	HC Wainwright	Set Price Target	Buy	$25.00	Low
5/28/2019	HC Wainwright	Set Price Target	Buy	$25.00	Medium
3/26/2019	HC Wainwright	Set Price Target	Buy	$25.00	High
3/8/2019	Canaccord Genuity	Set Price Target	Buy	$21.00	High
3/5/2019	HC Wainwright	Set Price Target	Buy	$25.00	Medium
2/5/2019	HC Wainwright	Set Price Target	Buy	$25.00	High
1/4/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	Medium
12/12/2018	HC Wainwright	Reiterated Rating	Buy	$25.00	Medium
8/10/2018	Canaccord Genuity	Reiterated Rating	Buy	$21.00	Low
8/1/2018	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
7/3/2018	Canaccord Genuity	Reiterated Rating	Buy	$21.00	High
6/12/2018	HC Wainwright	Reiterated Rating	Buy	$25.00	High
5/3/2018	HC Wainwright	Initiated Coverage	Buy	$25.00	High
4/2/2018	Canaccord Genuity	Initiated Coverage	Buy	$21.00	High
4/2/2018	BMO Capital Markets	Initiated Coverage	Outperform	$23.00	High
4/2/2018	UBS Group	Initiated Coverage	Buy	$18.00	High
4/2/2018	Barclays	Initiated Coverage	Overweight ➝ Overweight	$15.00	High

(Data available from 7/25/2016 forward)

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $24.86

$24.72

$25.78

50 Day Range

MA: $31.78

$24.86

$38.83

52 Week Range

Now: $24.86

$24.72

$67.74

Volume

255,628 shs

Average Volume

490,036 shs

Market Capitalization

$612.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of BioXcel Therapeutics?

The following sell-side analysts have issued reports on BioXcel Therapeutics in the last year: Berenberg Bank, BMO Capital Markets, Canaccord Genuity, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., The Goldman Sachs Group, Inc., Truist, Truist Financial Co., Truist Securities, and UBS Group AG.
View the latest analyst ratings for BTAI.

What is the current price target for BioXcel Therapeutics?

10 Wall Street analysts have set twelve-month price targets for BioXcel Therapeutics in the last year. Their average twelve-month price target is $102.00, suggesting a possible upside of 310.3%. HC Wainwright has the highest price target set, predicting BTAI will reach $140.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $60.00 for BioXcel Therapeutics in the next year.
View the latest price targets for BTAI.

What is the current consensus analyst rating for BioXcel Therapeutics?

BioXcel Therapeutics currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BTAI will outperform the market and that investors should add to their positions of BioXcel Therapeutics.
View the latest ratings for BTAI.

What other companies compete with BioXcel Therapeutics?

Other companies that are similar to BioXcel Therapeutics include OPKO Health, ALX Oncology, Verve Therapeutics, Corcept Therapeutics, Amicus Therapeutics, Arcus Biosciences, Prothena, Morphic, Nuvation Bio, Revance Therapeutics, MorphoSys, Ironwood Pharmaceuticals, Zentalis Pharmaceuticals, Cytokinetics and Atea Pharmaceuticals.

How do I contact BioXcel Therapeutics' investor relations team?

BioXcel Therapeutics' physical mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company's listed phone number is 475-238-6837 and its investor relations email address is [email protected] The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.